Interferon beta-1a and beta-1b for treatment of multiple sclerosis [5] (multiple letters)

Lancet

Volumn 360, Issue 9343, 2002, Pages 1428-1429

  Kappos, L ^a   Benatar, Michael ^b   Durelli, L ^c  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^c UNIVERSITY OF TURIN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BETA1A INTERFERON; CYCLOPHOSPHAMIDE; INTERFERON BETA SERINE; BETA INTERFERON; IMMUNOLOGICAL ADJUVANT; INTERFERON BETA-1B;

BRAIN INJURY; CALCULATION; CLINICAL TRIAL; DISABILITY; DISEASE SEVERITY; DRUG EFFICACY; DRUG MEGADOSE; ERROR; FOLLOW UP; HUMAN; LETTER; METHODOLOGY; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PRACTICE GUIDELINE; PRIORITY JOURNAL; RELAPSE; STATISTICAL SIGNIFICANCE; SURVIVAL; TREATMENT OUTCOME; NOTE; DRUG ADMINISTRATION; PHASE 3 CLINICAL TRIAL; TIME;

ADJUVANTS, IMMUNOLOGIC; CLINICAL TRIALS; HUMANS; INTERFERON-BETA; MULTIPLE SCLEROSIS; CLINICAL TRIALS, PHASE III; DRUG ADMINISTRATION SCHEDULE; TIME FACTORS; TREATMENT OUTCOME;

EID: 0037010368     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0140-6736(02)11384-5     Document Type: Letter

References (2)

1. BG Weinshenker GP Rice JH Noseworthy W Carriere J Baskerville GC Ebers The natural history of multiple sclerosis: a geographically based study, 3: multivariate analysis of predictive factors and models of outcome Brain 114 1991 1045 1056
2. GPA Rice AB Incorvaia L Munari Interferon in relapsing-remitting multiple sclerosis The Cochrane Library. Issue 4 2001 Update Software Oxford